(Q30769548)

26 June 2017

1 reference

1 reference

title

How useful are unpublished data from the Food and Drug Administration in meta-analysis? (English)

1 reference

26 June 2017

1 reference

5

Paul G Shekelle

1 reference

26 June 2017

Catherine H MacLean

1

1 reference

26 June 2017

Sally C Morton

2

1 reference

26 June 2017

Joshua J Ofman

3

1 reference

26 June 2017

Elizabeth A Roth

4

1 reference

26 June 2017

Southern California Evidence-Based Practice Center

6

1 reference

26 June 2017

publication date

1 January 2003

1 reference

Journal of Clinical Epidemiology

26 June 2017

published in

1 reference

26 June 2017

volume

56

1 reference

26 June 2017

issue

1

1 reference

26 June 2017

page(s)

44-51

1 reference

Should unpublished data be included in meta-analyses? Current convictions and controversies

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

1 reference

7 January 2021

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

The importance of quality of primary studies in producing unbiased systematic reviews

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

The uncertainty principle and industry-sponsored research

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

Funding clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

Coefficient alpha and the internal structure of tests

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

Definition and investigation of dyspepsia. Consensus of an international ad hoc working party

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

AGA technical review: evaluation of dyspepsia. American Gastroenterological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness.

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

Some statistical methods for combining experimental results

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

Comprehensive geriatric assessment: a meta-analysis of controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

Antrafenine, naproxen and placebo in osteoarthritis: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

A double-blind study comparing ibuprofen 1800 mg or 2400 mg daily and placebo in sports injuries

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

A controlled endoscopic study comparing the toxic effects of sulindac, naproxen, aspirin, and placebo on the gastric mucosa of health volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0895-4356%2802%2900520-6

7 January 2021

10.1016/S0895-4356(02)00520-6

Identifiers

DOI

1 reference

26 June 2017

1 reference